+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating KarXT for the treatment of schizophrenia in adolescents aged 13 to 17 years. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of KarXT in this population experiencing active symptoms of psychosis. The study is sponsored by Bristol-Myers Squibb and focuses on improving schizophrenia symptoms as measured by standard clinical scales. Participants will be randomly assigned to receive either KarXT or a matching placebo with specified doses on designated days. The study uses a parallel design with quadruple masking to compare outcomes between the two groups. The primary treatment phase lasts 5 weeks, during which the effects of KarXT on schizophrenia symptoms will be closely monitored. During the study, participants will undergo assessments including the Positive and Negative Syndrome Scale PANSS, Clinical Global Impression-Severity CGI-S, and Childrens Global Assessment Scale CGAS at baseline and Week 5. These measures track changes in symptom severity and overall functioning. Safety and tolerability will also be evaluated throughout the trial, which is expected to complete by December 2029.

Age: 13Years - 17YearsAll GendersPhase 3
37 locations
W

Actively Recruiting

Researchers are evaluating the efficacy and safety of cariprazine in treating schizophrenia among adolescents aged 13 to 17 years. This international, multicenter study is designed as a randomized, double-blind, placebo-controlled trial to understand how cariprazine affects symptoms of schizophrenia in this younger population. Participants will be randomly assigned to receive either cariprazine capsules at doses of 1.5 mg or 4.5 mg once daily, or matching placebo capsules once daily. The treatment phase lasts for six weeks, during which participants take the assigned capsules orally every day. During the study, participants will be monitored regularly to assess changes in their schizophrenia symptoms using the Positive and Negative Syndrome Scale PANSS. Researchers will also evaluate safety and tolerability throughout the trial. The main measurement is the change in PANSS total score from the start to the end of the six-week period. The study is designed to last until December 2026.

Age: 13Years - 17YearsAll GendersPhase 3
57 locations
E

Actively Recruiting

Researchers are studying the effects of lumateperone in children and teenagers aged 10 to 17 who have major depressive episodes linked to bipolar I or bipolar II disorder. This is a multicenter, randomized, double-blind study comparing lumateperone to a placebo to understand its potential impact on bipolar depression in pediatric patients. The diagnosis is confirmed using a structured psychiatric interview following DSM-5 criteria. Participants will take either lumateperone or a matching placebo once daily during a 6-week double-blind treatment period. Dosage varies by age, with patients aged 13 to 17 receiving 42 mg and those aged 10 to 12 receiving 21 mg. The study is divided into three phases an initial screening period of up to 2 weeks, the 6-week treatment phase, and a 1-week safety follow-up after the last dose. During the study, participants will undergo assessments including the Childrens Depression Rating Scale-Revised CDRS-R to measure depression severity. Safety will be monitored throughout the trial with a follow-up visit about one week after treatment ends. The study aims to evaluate changes in depressive symptoms over the 6-week treatment, with all visits and assessments scheduled accordingly.

Age: 10Years - 17YearsAll GendersPhase 3
68 locations
E

Actively Recruiting

Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.

Age: 18Years - 74YearsAll GendersPhase 3
205 locations
O

Actively Recruiting

Researchers are evaluating the safety and tolerability of lumateperone in children and adolescents diagnosed with schizophrenia, bipolar disorder, or autism spectrum disorder. This open-label, multicenter study lasts 26 weeks and aims to better understand how this medication affects pediatric patients with these conditions. The study includes patients who are either new to treatment or rolling over from previous related studies. Participants will receive lumateperone once daily in capsule or orally disintegrating tablet form, with doses ranging from 5 mg to 42 mg based on their age and condition. The trial begins with a screening period up to 2 weeks to confirm eligibility, followed by a 26-week treatment phase where all participants receive open-label lumateperone. After treatment, there is a 2-week safety follow-up visit approximately 2 weeks after the last dose. Throughout the study, participants will attend clinic visits for monitoring and assessments. Researchers will collect safety data, including tracking common adverse events up to six months. Patients must be outpatients expected to remain so during the study. Safety follow-up helps ensure ongoing monitoring after treatment ends, with the entire participation lasting about 28 weeks including screening and follow-up.

Age: 5Years - 17YearsAll GendersPhase 3
65 locations
P

Actively Recruiting

This research aims to compare changes in body mass index BMI Z-score in children and adolescents diagnosed with schizophrenia or bipolar I disorder. The study evaluates the effects of two treatments a fixed-dose combination of olanzapine and samidorphan OLZSAM versus olanzapine alone. It is a phase 3, randomized, double-blind trial designed to assess weight gain and related clinical outcomes in pediatric patients. Participants are randomly assigned to receive either OLZSAM or olanzapine. The starting dose of olanzapine is 2.5 mgday or 5 mgday, adjusted by the investigator, with a maximum of 20 mgday. Samidorphan is dosed at 5 or 10 mg. The study lasts up to 52 weeks, with primary weight change assessments at 12 weeks. Treatment groups are compared to monitor changes in BMI Z-score and other clinical measures. Throughout the study, participants undergo regular evaluations including BMI measurements, waist circumference, and psychiatric assessments such as the Positive and Negative Syndrome Scale PANSS for schizophrenia and Young Mania Rating Scale YMRS for bipolar I disorder. Safety is closely monitored by tracking adverse events and treatment discontinuation. The study includes outpatient visits with continued follow-up for up to one year to observe long-term effects on weight and psychiatric symptoms.

Age: 10Years - 17YearsAll GendersPhase 3
47 locations